A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
Active, not recruiting · Phase 1, Phase 2 · NCT06660667
Conditions: Neovascular Age-related Macular Degeneration
At a glance
- Research payments reported, 2025
- $1.3M
- U.S. investigators named
- 20
- Sites paid
- 22
- Planned or actual enrollment
- 66
About the trial
- Sponsor
- Sanofi
- Tested
- SAR402663 (biological), Diluent (drug)
- Dates
- Started 2024-11-21; completion 2031-06-30
- Results posted
- Not yet
This is a Phase 1/Phase 2 multicenter study to evaluate the safety and efficacy of a one-time single-eye intravitreal dose of SAR402663 in participants with neovascular age-related macular degeneration. Participants will be enrolled in one of 2 parts: * In Part I (dose escalation), multiple dose levels of SAR402663 will be evaluated in successive cohorts of participants * In Part II (dose expansion), participants will be randomized to receive one of two dose levels selected based on data from Part I. Participants, investigators and outcomes assessors will be masked to dose. After receiving one-time dose of SAR402663, participants will undergo regular assessments over 12 months. Following …
From ClinicalTrials.gov, last updated 2026-07-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $1.3M in research payments for this study in 2025 (156 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Benjamin B. Bakall, M.D., PH.D. Retina Specialist · Phoenix, AZ
- Pouya N. Dayani, M.D. Ophthalmology · Los Angeles, CA
- Dilsher S. Dhoot, M.D. Retina Specialist · Santa Barbara, CA
- David A. Eichenbaum, M.D. Ophthalmology · St Petersburg, FL
- Christine N. Kay, M.D. Ophthalmology · Gainesville, FL
- Dennis M. Marcus, M.D. Ophthalmology · Augusta, GA
- Veeral Sheth, M.D. Ophthalmology · Oak Forest, IL
- Jeffrey S. Heier Retina Specialist · Boston, MA
- Allen Y. Hu, MD Ophthalmology · Hagerstown, MD
- Arshad M. Khanani, M.D. Ophthalmology · Reno, NV
- Albert O. Edwards, MD, PHD Retina Specialist · Eugene, OR
- Daniel Alfaro III, M.D. Ophthalmology · Charleston, SC
- Stephen M. Huddleston, M.D. Retina Specialist · Germantown, TN
- Ashkan M. Abbey, M.D. Ophthalmology · Dallas, TX
- David Brown, M.D. Ophthalmology · Houston, TX
- Chirag D. Jhaveri, M.D. Ophthalmology · Austin, TX
- Richard G. Lane II, M.D. Retina Specialist · San Antonio, TX
- Fuad Makkouk, MD Ophthalmology · Austin, TX
- Michael A. Singer, M.D. Ophthalmology · San Antonio, TX
- Charles C. Wykoff, MD, PHD Ophthalmology · Bellaire, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sierra Eye Associates $269,477
- Texas Retina Associates $169,882
- Doctrials Llc $126,799
- University Retina $122,179
- Retina Consultants of Houston $80,769
- Cumberland Valley Retina Consultants PC 1800 Dual Highway $70,402
- Nvision Austin Clinical Research Mso Llc $60,104
- Pautler Cohen Findlay and Eichenbaum MDs PA $58,658
- Southeast Retina Center, PC $49,497
- Retina Vitreous Associates Medical Group $48,854
- Ophthalmic Consultants of Boston $39,315
- Austin Clinical Research, Llc $32,750
- Vitreoretinal Associates $28,031
- Verum Research, Llc $27,631
- California Retina Consultants $26,923
- Charleston Neurosciences Institute $26,923
- University Retina and Macula Associates $16,065
- Medical Center Opthalmology Associate $14,305
- Southeast Retina Center PC $11,237
- 0100267916 Charles Retina Institute $10,237
- Retina Vitreous Associates of Fl $1,905
- Prohealth Research Center $1,114
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.